I Rhythm Technologies, Inc. IRTC
We take great care to ensure that the data presented and summarized in this overview for iRhythm Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRTC
View all-
Vanguard Group Inc Valley Forge, PA3.11MShares$413 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.02MShares$401 Million1.14% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.81MShares$374 Million0.51% of portfolio
-
Black Rock Inc. New York, NY2.5MShares$333 Million0.01% of portfolio
-
Capital Research Global Investors Los Angeles, CA2.2MShares$293 Million0.05% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A61.16MShares$154 Million0.18% of portfolio
-
State Street Corp Boston, MA918KShares$122 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL903KShares$120 Million0.02% of portfolio
-
Bnp Paribas Asset Management Holding S.A.880KShares$117 Million0.25% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT823KShares$109 Million0.66% of portfolio
Latest Institutional Activity in IRTC
Top Purchases
Top Sells
About IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at IRTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 07
2025
|
Kevin C Oboyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,035
+50.0%
|
-
|
|
Jul 07
2025
|
Karen K Mcginnis Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,035
+50.0%
|
-
|
|
Jul 02
2025
|
Minang Turakhia EVP, CMO & CSO |
SELL
Open market or private sale
|
Direct |
1,420
-3.32%
|
$205,900
$145.41 P/Share
|
|
Jul 01
2025
|
Sean Clinton Freeman EVP, Strategy & Corp Devt |
BUY
Grant, award, or other acquisition
|
Direct |
6,761
+50.0%
|
-
|
|
Jun 23
2025
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
936
-1.88%
|
$140,400
$150.0 P/Share
|
|
Jun 23
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.93%
|
$450,000
$150.0 P/Share
|
|
Jun 10
2025
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
363
-0.72%
|
$54,450
$150.0 P/Share
|
|
Jun 02
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
696
-5.9%
|
$97,440
$140.21 P/Share
|
|
Jun 02
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
1,608
-4.43%
|
$225,120
$140.21 P/Share
|
|
May 30
2025
|
Minang Turakhia EVP, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
318
+0.74%
|
$23,532
$74.72 P/Share
|
|
May 30
2025
|
Quentin S. Blackford President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
297
+0.14%
|
$21,087
$71.46 P/Share
|
|
May 30
2025
|
Chad Patterson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
298
+0.59%
|
$21,158
$71.46 P/Share
|
|
May 30
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
294
+2.43%
|
$20,874
$71.46 P/Share
|
|
May 30
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
176
+0.48%
|
$12,496
$71.46 P/Share
|
|
May 28
2025
|
Ralph Snyderman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+9.27%
|
-
|
|
May 28
2025
|
Bruce G. Bodaken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+9.7%
|
-
|
|
May 28
2025
|
Brian B Yoor Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+19.52%
|
-
|
|
May 28
2025
|
Mark J Rubash Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+8.97%
|
-
|
|
May 28
2025
|
Karen Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+12.43%
|
-
|
|
May 28
2025
|
Abhijit Y Talwalkar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+6.27%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 269K shares |
|---|---|
| Open market or private purchase | 6.66K shares |
| Other acquisition or disposition | 110 shares |
| Open market or private sale | 133K shares |
|---|